We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

176 hedge funds and large institutions have $2.44B invested in Celldex Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 55 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more call options, than puts

Call options by funds: $61.1M | Put options by funds: $35.8M

24% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 55

2.74% more ownership

Funds ownership: 105.59% → 108.33% (+2.7%)

3% less funds holding

Funds holding: 182 → 176 (-6)

5% less capital invested

Capital invested by funds: $2.58B → $2.44B (-$135M)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
176
Holders Change
-6
Holders Change %
-3.3%
% of All Funds
2.53%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
22
Increased
68
Reduced
55
Closed
28
Calls
$61.1M
Puts
$35.8M
Net Calls
+$25.3M
Net Calls Change
+$39M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$66.1M
2
WP
Woodline Partners
California
+$60.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$44.5M
4
Goldman Sachs
Goldman Sachs
New York
+$36.6M
5
LGM
Logos Global Management
California
+$34.3M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$68.8M
2
Marshall Wace
Marshall Wace
United Kingdom
-$42M
3
SI
Sofinnova Investments
California
-$20.3M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.1M
5
PCH
Polar Capital Holdings
United Kingdom
-$13.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ensign Peak Advisors
101
Ensign Peak Advisors
Utah
$796K – – –
Wells Fargo
102
Wells Fargo
California
$762K -$12.4K -325 -1%
New York State Common Retirement Fund
103
New York State Common Retirement Fund
New York
$756K -$286K -7,500 -25%
VOYA Investment Management
104
VOYA Investment Management
Georgia
$714K -$19.3K -507 -2%
JFG
105
Jefferies Financial Group
New York
$714K +$800K +21,000 New
Assenagon Asset Management
106
Assenagon Asset Management
Luxembourg
$712K -$4.5M -118,216 -85%
SG Americas Securities
107
SG Americas Securities
New York
$691K +$429K +11,272 +125%
PA
108
Profund Advisors
Maryland
$631K -$150K -3,945 -18%
BHCM
109
Brevan Howard Capital Management
Jersey
$606K +$262K +6,870 +63%
ASRS
110
Arizona State Retirement System
Arizona
$581K +$32.3K +849 +5%
GCP
111
GSA Capital Partners
United Kingdom
$548K +$403K +10,581 +191%
Teacher Retirement System of Texas
112
Teacher Retirement System of Texas
Texas
$506K +$81.7K +2,145 +17%
Creative Planning
113
Creative Planning
Kansas
$504K +$565K +14,819 New
State Board of Administration of Florida Retirement System
114
State Board of Administration of Florida Retirement System
Florida
$494K – – –
PD
115
Point72 (DIFC)
United Arab Emirates
$480K +$271K +7,116 +102%
Zurich Cantonal Bank
116
Zurich Cantonal Bank
Switzerland
$480K – – –
Handelsbanken Fonder
117
Handelsbanken Fonder
Sweden
$469K +$99.1K +2,600 +23%
ProShare Advisors
118
ProShare Advisors
Maryland
$415K +$148K +3,882 +47%
TRCT
119
Tower Research Capital (TRC)
New York
$364K -$91.3K -2,396 -18%
CAC
120
Cowen and Company
New York
$364K +$408K +10,700 New
DnB Asset Management
121
DnB Asset Management
Norway
$346K +$87.5K +2,297 +29%
PAMP
122
Polar Asset Management Partners
Ontario, Canada
$330K -$72.4K -1,900 -16%
FRM
123
Fox Run Management
Connecticut
$317K +$355K +9,324 New
HS
124
HighVista Strategies
Massachusetts
$305K -$24.6K -646 -7%
Victory Capital Management
125
Victory Capital Management
Texas
$277K -$6.55K -172 -2%
3 4
5
6 7

CLDX Hedge Fund Activity: Q3 2024 in Review

176 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2024, worth a combined $2.44B — down 5.2% from $2.58B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CLDX and 22 opened new positions — a net loss of 6 holders — while 55 trimmed existing stakes and 68 added.

The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $66.1M. The largest seller was Fidelity Investments, cutting an estimated $68.8M.

  • 176 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2024, down from 182 in Q2 2024.
  • Funds reported $2.44B of Celldex Therapeutics stock for Q3 2024, down 5.2% quarter-over-quarter.
  • 22 funds opened new Celldex Therapeutics positions in Q3 2024 and 28 closed out, a net change of -6 holders.
  • The largest Celldex Therapeutics buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $66.1M added.
  • The largest Celldex Therapeutics seller in Q3 2024 was Fidelity Investments, an estimated $68.8M sold.

Based on aggregated 13F filings for Q3 2024.